Company: PRME
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0001628280-25-008884
Chunk: 234

Company: Prime Medicine, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 234
---
uances of common stock upon exercise of stock options28,048 — 103 — — 103 Stock-based compensation expense— — 26,068 — — 26,068 Change in unrealized loss on investments, net of tax— — — 16 — 16 Net loss— — — — (195,882)(195,882)Balances at December 31, 2024131,160,842 $2 $840,358 $1 $(687,212)$153,149 

The accompanying notes are an integral part of these consolidated financial statements.

F-5

PRIME MEDICINE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

Year Ended December 31,(in thousands)20242023Cash flows used in operating activities:Net loss$(195,882)$(198,133)Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation expense26,068 13,910 Non cash lease expense12,355 12,788 Depreciation expense6,128 4,653 Change in fair value of short-term investment — related party484 2,382 Loss on disposal of property and equipment— 28 Amortization of premiums and discount on short-term investments(3,094)(3,408)Deferred income taxes— (279)Changes in operating assets and liabilities:Prepaid expenses and other current assets(15,859)(9,455)Accounts payable(5,257)9,140 Accrued expenses and other current liabilities1,843 1,758 Accrued settlement payment — related party(13,500)13,500 Deferred revenue — related party70,310 — Lease liability(6,461)(12,296)Net cash used in operating activities(122,865)(165,412)Cash flows provided by investing activities:Maturities of investments204,200 132,556 Purchases of investments(129,449)(104,951)Purchases of property and equipment(7,294)(8,724)Return (payment) of security deposit1,000 (170)Net cash provided by investing activities68,457 18,711 Cash flows provided by financing activities:Proceeds from follow-on offering, net of issuance costs132,055 — Proceeds from issuance of pre-funded warrants, net of